Haematopoietic stem cell
Haematopoietic stem cell transplantation at the Clínica
The extraction of the cell product used for the transplantation is conducted in an outpatient setting in the Therapeutic Apheresis Unit, which has next-generation cell processors in individual rooms.
Our specialists in haematology and haemotherapy, oncology, immunology and paediatrics for younger patients, perform these processes with maximum safety and performance.
The processing of cell products for transplantation is conducted in the Cell Therapy GMP Laboratory under a strict quality assurance system. It is a facility with ultrafiltered sterile air, which offers the most secure conditions for the preparation of products for each patient.
The decision about the most appropriate transplantation in each case is made individually, taking into account various factors. This type of transplantation is performed both for treating solid tumours and for haematologic tumours.
The Medical Unit for Haematopoietic Transplantation, where the transplantation and hospitalisation are conducted, consists of individual rooms with treatment systems and ultrafiltered air.
Haematopoietic stem cell transplantation can be performed from a healthy donor, generally a compatible sibling. If this option is not available, cells obtained from another compatible family member can be used.
The cells can also be obtained from an individual without a familial connection. In this case, the individual must be found among the volunteer donors registered in various countries.
From the umbilical cord
In some cases, transplantations can be performed with cells obtained from umbilical cord blood.
These transplants from donors are known as allogeneic transplants and are the most frequently used when the disease mainly affects the bone marrow.
Haematopoietic stem cell transplantation can be also performed with cells from the patients themselves. This is generally performed for neoplastic diseases when the bone marrow is not affected or when the disease has been eliminated from the bone marrow.
Haematopoietic stem cells can be obtained directly from the bone marrow in the operating room or, more typically, from the peripheral blood using a machine (an apheresis machine). When the machine is connected to a vein, it causes the blood to pass through a circuit. Centrifugation then separates the blood cells and selects the cells for collection while returning the rest to the patient.
Haematopoietic transplantation, the main activity of Cell Therapy Area
Haematopoietic stem cell transplantation (bone marrow transplantation) is the main healthcare activity of Clinic's Cell Therapy Area.
It is conducted through a multidisciplinary structure in which the following departments participate: Haematology, Oncology, Paediatrics, Blood Bank and Immunology. The extraction of the cell product used for the transplantation is conducted in an outpatient setting in the Therapeutic Apheresis Unit, located in the Clinic's Outpatient Centre. This unit has next-generation cell processors in individual rooms.
Medical specialists in haematology and haemotherapy and more than 12 nurses (experts in therapeutic apheresis) perform these processes with the maximum safety and performance.
The processing of cell products for transplantation is conducted in the Cell Therapy GMP Laboratory under a strict quality assurance system. It is a facility with white rooms and ultrafiltered sterile air, which offers maximum security in the preparation of products for each patient. The Medical Unit for Haematopoietic Transplantation, where the transplantation and hospitalisation are conducted, consists of 5 individual rooms with treatment systems and ultrafiltered air, which ensure optimal conditions for immunocompromised patients. The medical care is the responsibility of a team of experts in haematopoietic transplantation. Patients can access innovative treatments developed through clinical research trials.
The Haematopoietic Transplantation Area is currently conducting open clinical trials for pretransplant conditioning with radioimmunotherapy (for both autologous and allogeneic transplantation) and for the treatment of graft-versus-host disease using mesenchymal bone marrow stem cells produced in the GMP Laboratory.